Literature DB >> 15550401

Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.

Ian Colman1, Michael D Brown, Grant D Innes, Eric Grafstein, Ted E Roberts, Brian H Rowe.   

Abstract

OBJECTIVE: To assess the evidence from controlled trials on the efficacy and tolerability of parenteral metoclopramide for acute migraine in adults. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS, CINAHL, conference proceedings, clinical practice guidelines, and other sources. SELECTION CRITERIA: Randomised controlled trials of parenteral metoclopramide for acute migraine in adults.
RESULTS: We reviewed 596 potentially relevant abstracts and found 13 eligible trials totalling 655 adults. In studies comparing metoclopramide with placebo, metoclopramide was more likely to provide significant reduction in migraine pain (odds ratio 2.84, 95% confidence interval 1.05 to 7.68). Used as the only agent, metoclopramide showed mixed effectiveness when compared with other single agents. Heterogeneity of studies for combination treatment prevented statistical pooling. Treatments that did include metoclopramide were as, or more, effective than comparison treatments for pain, nausea, and relapse outcomes reported in all studies.
CONCLUSIONS: Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments. Given its non-narcotic and antiemetic properties, metoclopramide should be considered a primary agent in the treatment of acute migraines in emergency departments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550401      PMCID: PMC535449          DOI: 10.1136/bmj.38281.595718.7C

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Guidelines for controlled trials of drugs in migraine: second edition.

Authors:  P Tfelt-Hansen; G Block; C Dahlöf; H C Diener; M D Ferrari; P J Goadsby; V Guidetti; B Jones; R B Lipton; H Massiou; C Meinert; G Sandrini; T Steiner; P B Winter
Journal:  Cephalalgia       Date:  2000-11       Impact factor: 6.292

2.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

3.  Burden of migraine in the United States: disability and economic costs.

Authors:  X H Hu; L E Markson; R B Lipton; W F Stewart; M L Berger
Journal:  Arch Intern Med       Date:  1999-04-26

4.  A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department.

Authors:  D S Tek; D S McClellan; J S Olshaker; C L Allen; D C Arthur
Journal:  Ann Emerg Med       Date:  1990-10       Impact factor: 5.721

5.  Metoclopramide in migrane treatment.

Authors:  J B Hughes
Journal:  Med J Aust       Date:  1977-10-22       Impact factor: 7.738

6.  Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.

Authors:  K R Edwards; J Norton; M Behnke
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

7.  A double blind study of metoclopramide in the treatment of migraine attacks.

Authors:  P Tfelt-Hansen; J Olesen; A Aebelholt-Krabbe; B Melgaard; B Veilis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

Review 8.  Metoclopramide--a review.

Authors:  P V Desmond; K J Watson
Journal:  Med J Aust       Date:  1986-03-31       Impact factor: 7.738

9.  Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache.

Authors:  M J Belgrade; L J Ling; M B Schleevogt; M G Ettinger; E Ruiz
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

10.  Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches.

Authors:  J A Klapper; J S Stanton
Journal:  Headache       Date:  1991-09       Impact factor: 5.887

View more
  36 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

2.  Phenothiazines in migraine treatment.

Authors:  Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2010-08

Review 3.  Diagnosis and management of the primary headache disorders in the emergency department setting.

Authors:  Benjamin Wolkin Friedman; Brian Mitchell Grosberg
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

4.  Recent Advances in Pharmacotherapy for Episodic Migraine.

Authors:  Calvin Chan; Peter J Goadsby
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

5.  Use of dopamine antagonists in treatment of migraine.

Authors:  Michael J Marmura
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

6.  Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia.

Authors:  R Kagan; V Kainz; R Burstein; R Noseda
Journal:  Neuroscience       Date:  2013-06-25       Impact factor: 3.590

7.  Treatment of acute migraine in the emergency department.

Authors:  Saurabh Gupta; Richard Oosthuizen; Simon Pulfrey
Journal:  Can Fam Physician       Date:  2014-01       Impact factor: 3.275

Review 8.  Aspirin with or without an antiemetic for acute migraine headaches in adults.

Authors:  Varo Kirthi; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 9.  Acute treatment of migraines.

Authors:  Arnaldo N Da Silva; Stewart J Tepper
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

10.  Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study.

Authors:  Alfredo I Niño-Maldonado; Gary Caballero-García; Wilfrido Mercado-Bochero; Fernando Rico-Villademoros; Elena P Calandre
Journal:  Head Face Med       Date:  2009-11-08       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.